eli lilly tirzepatide patent https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound Republican Administration Maintains Exclusivity Stance

Semaglutide GLP-1 works by mimicking the action of the hormone GLP-1 (glucagon-like peptide), which is responsible for controlling appetite and glucose levels

Health insurers will be well served to begin quantifying GLP-1s cost impact on the portfolio for the short and long term, which will vary by market and product, to determine any necessary premium adjustments or changes to underwriting philosophy

Fried foods contain more calories than non-fried foods, which can contribute to weight gain

Mounjaro belongs to the class of medications called dual GIP/GLP-1 receptor agonists (glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists)